Clinical Trial Update: A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors. [Phase 1]

View source ↗

Summary

Phase 1 clinical study evaluating the safety of Lutetium-177 DOTATATE peptide receptor radionuclide therapy in children with neuroblastoma expressing somatostat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Lutetium-177 dotatate (Lutetium-177 dotatate)

Snippet

Sponsor: Institut Claudius Regaud | Conditions: Neuroblastoma | Phase 1 | Status: RECRUITING